New Data and Clinical Factors Contributing to CDK4/6 Inhibitor Selection
Two breast cancer experts delve into key data from various CDK4/6 inhibitor studies, focusing on safety, efficacy, and how these agents might be implemented in the clinic.
EP: 1.Introduction to the HR+ Treatment Landscape
EP: 2.Disparities in Clinical Trials of HR+ Breast Cancer
EP: 3.New Data and Clinical Factors Contributing to CDK4/6 Inhibitor Selection
EP: 4.Exploring Treatment Options After First Line CDK4/6 Inhibitor plus Endocrine Therapy
EP: 5.Additional Perspectives on Treatment Selection and Sequencing in Metastatic Breast Cancer
EP: 6.Emerging Data on HER2-Low Breast Cancer and Clinical Implications
EP: 7.Looking Forward: Breast Cancer Treatment in 2023 and Beyond
EP: 8.Recap: Real-world Application of Updated Breast Cancer Results
NCCN Guideline Updates in HR+ Breast Cancer: Focus on Extended Adjuvant Therapy
August 17th 2021This article reviews NCCN Guideline updates regarding the use of genomic assays in predicting the benefit of extended adjuvant endocrine therapy in patients with HR+ breast cancer and includes insights from Lee S. Schwartzberg, MD, of West Cancer Center at the University of Tennessee Health Science Center in Memphis, TN.
Individualizing Extended Adjuvant Therapy in HR+ Breast Cancer
June 15th 2021This article reviews individualizing extended adjuvant therapy for patients with HR+ breast cancer and includes insights from Vijayakrishna (V. K.) Gadi, MD, PhD, of the University of Illinois in Chicago, and Reshma L. Mahtani, DO, of the University of Miami Health System in Deerfield Beach, FL.
Advances in Later-Line Management of Relapsed/Refractory Follicular Lymphoma
May 27th 2021This article reviews advances in later-line management of relapsed/refractory follicular lymphoma. This article also features insights from oncology expert Sameh Gaballa, MD, of Moffitt Cancer Center in Tampa, Florida.
